A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaChan Y. Cheah, John F. Seymour, David Ritchie et al.|British Journal of Cancer|2014Cited by 132
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human TrialConstantine S. Tam, Andrew W. Roberts, Andrew Grigg et al.|Blood|2015Cited by 111
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Constantine S. Tam, Andrew W. Roberts, Stephen Opat et al.|Blood|2016Cited by 37
Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Mary Ann Anderson et al.|Blood Advances|2025Cited by 2